Dr. John G. Quigley
Hematology (Hematology (Internal Medicine) Physician)
1740 W Taylor St
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 86
Licensed in Illinois since 2004, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
IL license 036112424 (first issued 2004; active) -
Hematology & Oncology Physician
IL license 036112424 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Illinois Hospital and Clinics Chicago, IL
Medical groups
- The Board of Trustees of the University of Illinois (1,150 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 361
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 157 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 42 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| Hospital discharge day management, 30 minutes or less | 12 | 11 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calquence (acalabrutinib maleate) | 36 |
| Sprycel (dasatinib) | 13 |
| Hydroxyurea Other prescribers in Chicago, IL | 13 |
| Doptelet (avatrombopag maleate) | 12 |
| Vonjo (pacritinib citrate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 21 payments worth $27,197 in total to this clinician.
| Servier Pharmaceuticals LLC | $15,191 |
|---|---|
| Jazz Pharmaceuticals Inc. | $7,441 |
| Genzyme Corporation | $4,390 |
| Beigene USA, Inc. | $176 |
| Speaking at a medical education program | $14,620 |
|---|---|
| Consulting Fee | $10,901 |
| Travel and Lodging | $1,128 |
| Food and Beverage | $548 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Consulting Fee RYLAZE · HEMATOLOGY/ONCOLOGY | $6,696 |
| Servier Pharmaceuticals LLC Sep 26, 2025 | Speaking at a medical education program Tibsovo · Oncology | $6,460 |
| Genzyme Corporation May 13, 2025 | Consulting Fee | $4,205 |
| Servier Pharmaceuticals LLC Oct 17, 2025 | Speaking at a medical education program Tibsovo · Oncology | $3,740 |
| Servier Pharmaceuticals LLC Oct 23, 2025 | Speaking at a medical education program Tibsovo · Oncology | $3,740 |
| Servier Pharmaceuticals LLC May 16, 2025 | Speaking at a medical education program Tibsovo · Oncology | $680 |
| Servier Pharmaceuticals LLC Sep 17, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Hollywood, FL · in-kind | $457 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $277 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $225 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to chicago, IL · in-kind | $119 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC Oct 23, 2025 | Speaking at a medical education program Tibsovo · Oncology | $3,740 |
| Servier Pharmaceuticals LLC Oct 17, 2025 | Speaking at a medical education program Tibsovo · Oncology | $3,740 |
| Servier Pharmaceuticals LLC Sep 26, 2025 | Speaking at a medical education program Tibsovo · Oncology | $6,460 |
| Servier Pharmaceuticals LLC Sep 17, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Hollywood, FL · in-kind | $457 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Consulting Fee RYLAZE · HEMATOLOGY/ONCOLOGY | $6,696 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $277 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $225 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to chicago, IL · in-kind | $119 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $17.99 |
| Jazz Pharmaceuticals Inc. Aug 29, 2025 | Travel and Lodging RYLAZE · HEMATOLOGY/ONCOLOGY · travel to Indianapolis, IN · in-kind | $4.95 |
| Servier Pharmaceuticals LLC May 16, 2025 | Speaking at a medical education program Tibsovo · Oncology | $680 |
| Genzyme Corporation May 13, 2025 | Consulting Fee | $4,205 |
| Genzyme Corporation May 13, 2025 | Travel and Lodging travel to Chicago, IL | $27.83 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $69,459 in research payments for these studies, mostly to the institutions running them.
- A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.